Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Endoscopic removal of adenomas
What ifWhat if an endoscopic snare removed selected colorectal adenomas?
Claim language“a therapeutically effective amount of a compound of Formula I”
A colonoscope positions a wire loop around an adenoma, and the loop closes to sever the lesion. The retrieved tissue undergoes histologic examination, and follow-up endoscopy assesses the remaining mucosa for additional adenomas.
1.1Colon and rectum removal
What ifWhat if surgery removed the colon and rectum and used an ileal pouch to restore intestinal continuity?
Claim language“a therapeutically effective amount of a compound of Formula I”
Total proctocolectomy removes the colon and rectum, where colorectal adenomas arise. The surgeon folds the distal ileum into a reservoir and connects it to the anal canal.
1.2Direct acetyl substitution
What ifWhat if R9a were an acetyl group attached through its carbonyl carbon?
Claim language“H and optionally substituted C1-6 alkyl”
The group C(═O)CH3 places a carbonyl directly at the R9a attachment point. The carbonyl oxygen provides a hydrogen-bond acceptor.
1.2Direct cyclopropylcarbonyl substitution
What ifWhat if R9a were a cyclopropylcarbonyl group attached through its carbonyl carbon?
Claim language“H and optionally substituted C1-6 alkyl”
The carbonyl links the R9a attachment point to a three-membered carbon ring. The carbonyl oxygen accepts hydrogen bonds, and the ring constrains the geometry of the terminal group.
1.3Cyano substituted phenyl ring
What ifWhat if R10a were a phenyl ring with a cyano group opposite the attachment point?
The phenyl ring supplies a planar aromatic surface with six carbon ring atoms. The cyano nitrogen sits outside the ring and provides a hydrogen-bond acceptor.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Macrolide testing in intestinal organoids
A laboratory cultures patient-derived intestinal adenoma organoids in a multiwell plate. The operator adds the 13-membered macrolide to treatment wells and adds the same volume of vehicle to control wells. A microscope records each well before and after exposure, and image analysis measures changes in organoid area and count.
Component substitution
Cellulose shells for oral capsules
An oral unit dose uses a hypromellose capsule shell in place of a gelatin shell. The shell contains a measured fill of the macrolide or its salt blended with microcrystalline cellulose. Disintegration and dissolution tests measure shell opening and the amount of active ingredient released over time.
Parameter or scale variation
Two-stage dissolution at intestinal ph
An enteric-coated tablet contains a compressed core with the 13-membered macrolide. A paddle apparatus rotates at 50 revolutions per minute and holds the tablet in pH 1.2 medium for 2 hours before transfer to pH 6.8 buffer. During the buffer phase, samples are collected at 15, 30, 45, and 60 minutes and analyzed by liquid chromatography.
Combination with existing systems
Macrolide records linked to endoscopy
An endoscopy reporting system retrieves macrolide administration dates and recorded dose amounts from the medication record. Each procedure report stores polyp counts and measured diameters by bowel segment. A longitudinal view places medication records and procedure findings on the same timeline and displays the latest and baseline counts for each segment.
Macrolide dispensing in monitored blister packs
A blister pack holds one oral macrolide unit dose in each cavity and carries a conductive trace across each cavity seal. A reusable reader detects when a trace breaks and records the cavity identifier and opening time. A medication log displays the opening events alongside the prescribed schedule.
Automated or data-driven variant
Automated comparison of plasma exposure
An autosampler injects prepared plasma extracts into a liquid chromatography system coupled to a tandem mass spectrometer. The software calculates macrolide concentrations from the ratio of the analyte signal to an internal standard and aligns each result with elapsed time since the recorded dose. It calculates the area under the concentration-time curve by trapezoidal integration and flags samples outside the calibration range for review.
Specific version of a part
Terminal hydroxyl on ethyl
R9a is a 2-hydroxyethyl group with the structure CH2CH2OH. The first methylene attaches to the scaffold, and the terminal hydroxyl donates and accepts hydrogen bonds.
Pyridine attached through carbon three
R10a is a pyridin-3-yl group attached through carbon 3 of the aromatic ring. The ring nitrogen provides a hydrogen-bond acceptor two ring bonds from the attachment point.
Furan attached through carbon two
R10a is a furan-2-yl group attached through the carbon next to the ring oxygen. The five-membered ring provides a planar aromatic surface and an oxygen hydrogen-bond acceptor.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1administering to the patient a therapeutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof
In some embodiments, it is an aim to provide an improved method for the treatment of bacterial infections caused by β-lactamase producing bacteria in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound chosen from formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with one or more β-lactamase inhibitors, including the β-lactamase inhibitor of formula (II)
A · US 9,751,894 B2 · ¶ 103
The macrocyclic lactone cyclodextrin formed based on some or all of the above description is safely injectable at a dosage of approximately 20 to 400 micrograms per kilogram in an animal selecting the group consisting of swine, cattle, poultry, human, and husbanded animal. In this manner, Ivermectin or Ivermectin derivatives can be administered by way of injection, oral delivery, parenterally, or transmucosally whether through vaginal, rectal, nasal, buccal, ocular or any other mucosal surfaces.
B · US 11,253,533 B1 · ¶ 20
1.2wherein R9a is selected from a group consisting of H and optionally substituted C1-6 alkyl
In the formula (I), F is optionally substituted amidine or optionally substituted guanidine, and G is hydrogen, methyl, ethyl, C3-6 alkyl, C3-6 cycloalkyl or an optionally substituted 5- or 6-membered aliphatic or an optionally substituted 5- or 6-membered aromatic heterocyclic ring, in which the heterocyclic ring is substituted with at least 1-2 hetero atoms selected from N, O, and S (α or β).
A · US 9,751,894 B2 · ¶ 42
1.3R10a is an optionally substituted heteroaryl.
Wherein, R10 signifies a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl and substituted or unsubstituted heterocyclyl.
A · US 9,751,894 B2 · ¶ 64
An empty cell means only that no passage was reproduced there.
Statements in these documents
There is a demand for development of new cephem compounds which exhibit more potent antimicrobial activity in particular more effective against a variety of β-lactamase producing gram-positive and gram-negative bacteria.
A · US 9,751,894 B2 · ¶ 4
The present compounds, and pharmaceutically acceptable salts thereof, comprise different structural characteristics to known cephem compounds, providing improved antibacterial activity, particularly when used in combination with one or more β-lactamase inhibitors.
A · US 9,751,894 B2 · ¶ 8
Ivermectin further has a low solubility in water (about 0.005 mg per ml at 25 degrees Celsius).
B · US 11,253,533 B1 · ¶ 1
However, it was discovered that such micelle formulations were unstable and the Ivermectin degraded at such a rate as to render the shelf life inadequate for a commercial preparation.
B · US 11,253,533 B1 · ¶ 3
Cite aspatent.fyi, US 2026/0355228 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355228/, SHA-256 bc1cb199722932ed89b68b0b1b0fedad0281b0ae42054276b23506e2f79300ac